251 results
Page 5 of 13
8-K
EX-99.1
m4e5oqx8 o9sw6n
27 Apr 22
Alkermes plc Reports First Quarter 2022 Financial Results
7:07am
8-K
EX-99.2
fsqmp7 mp9qb
27 Apr 22
Alkermes plc Reports First Quarter 2022 Financial Results
7:07am
DEFA14A
0fjeg
16 Feb 22
Additional proxy soliciting materials
7:17am
8-K
EX-99.2
3e1ux6f
16 Feb 22
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
cp7sr
16 Feb 22
Results of Operations and Financial Condition
7:05am
DEFA14A
EX-99.2
qojtnykc
11 Jan 22
Additional proxy soliciting materials
7:02am
DEFA14A
EX-99.1
7tovyag xqwbw
11 Jan 22
Additional proxy soliciting materials
7:02am
8-K
EX-99.2
5vx9klgb56
11 Jan 22
Regulation FD Disclosure
7:00am
8-K
EX-99.1
bjoih95
11 Jan 22
Regulation FD Disclosure
7:00am
8-K
EX-99.1
4lle0u3zo bz3ydpts
19 Nov 21
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
7:08am
8-K
EX-99.1
hqag65i
8 Nov 21
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
4:17pm
8-K
EX-99.2
l41pb
27 Oct 21
Alkermes plc Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
hj3hh2nkb9w14wcxz5ln
27 Oct 21
Alkermes plc Reports Third Quarter 2021 Financial Results
7:05am
S-8
EX-5.1
wvxpb49y v9w18
28 Jul 21
Registration of securities for employees
4:19pm
8-K
EX-99.2
kq51i12euhzbd 3n
28 Jul 21
Alkermes plc Reports Second Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
kczkbt te
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am